Paracor Medical, Inc., a private venture-backed company developing device-based treatments for heart failure, today announced the closing of $44.35 million in its Series D funding. The round was led by new investor Aberdare Ventures, with the participation of Montagu Newhall Associates. All of the current institutional investors participated in the financing, including Delphi Ventures, Pequot Ventures, InterWest Partners, Alta Partners, DeNovo Ventures, RWI Ventures, Saratoga Ventures, and Palo Alto Investors. The new funds will primarily be used to support the recently initiated PEERLESS-HF pivotal clinical trial of the Company’s HeartNetTM device.
